Cureus
Mark A. Hallman
Create your FREE profile now!

Join the discussion with physicians and researchers around the globe - sign up for your free Cureus account today.

ADVERTISEMENT
About

My primary role is as a member of the thoracic oncology program treating lung cancer, mesothelioma and cancers of the thymus. I also treat genitourinary cancers including prostate cancer, bladder cancer, and testicular cancer. In addition I treat lymphoma and leukemia as a member of the hematologic malignancy program.

I have had extensive training in several specialized radiation techniques:

Intensity Modulated Radiation Therapy (IMRT)
Stereotactic Body Radiation Therapy (SBRT)
Prostate Brachytherapy
Treatment Philosophy

I earned doctorate degrees in both medicine and pharmacology research at the Medical University of South Carolina enrolled in the Medical Scientist Training Program. After graduation I joined Fox Chase Cancer Center for my medical residency training in the Department of Radiation Oncology. Upon completing residency I was recruited to become a member of the department faculty treating thoracic cancers, genitourinary cancers, and hematologic cancers. As part of that role, I will also be conducting research and designing clinical trials to both improve upon our current treatments and to develop new technologies in the fight against cancer.

While knowledge and expertise are important, I believe that compassion and personalized care are also essential to being an effective physician. I strive to establish trust and understanding with my patients in order to best help them complete complex and intense cancer therapies in order to achieve the best possible outcomes. This is an exciting time to be at Fox Chase Cancer Center. The faculty and staff at Fox Chase work as a team with the common goal of providing world class cancer treatment. Not only do I have access to state of the art technologies and cutting-edge treatments, but I also have the opportunity to develop new treatments that will improve the way we treat cancer in the future.

ADVERTISEMENT
Publications (2)
Show: